Will oral weight loss drugs challenge injectables?

Why are companies working so hard to make oral tablet forms of diabetes and weight loss drugs that target the glucagon-like peptide (GLP-1) receptor? The current injectable peptides – Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro and Zepbound (tirzepatide) – are incredibly successful, with potentially even more promising peptides in the pipeline. So why the rush to replace them with pills?